benefit
albumin
administr
larg
volum
resuscit
controversi
mani
year
although
recent
review
state
albumin
might
immunomodulatori
antiinflammatori
antioxid
properti
evid
albumin
fluid
resuscit
still
inconclus
multicent
random
parallel
openlabel
pragmat
trial
evalu
efficaci
longterm
human
albumin
administr
decompens
cirrhosi
total
patient
includ
studi
receiv
standard
treatment
combin
aldosteron
drug
furosemid
standard
treatment
plu
longterm
human
albumin
month
overal
surviv
rate
higher
standard
treatment
plu
longterm
albumin
standard
treatment
alon
group
vs
p
differ
nonliv
relat
advers
event
prospect
singleblind
studi
noncrit
ill
patient
n
undergo
elect
cystectomi
show
differ
renal
function
albumin
compar
balanc
hydroxyethyl
starch
volum
replac
renal
function
assess
analyz
serum
cystatin
c
concentr
estim
glomerular
filtrat
rate
risk
injuri
failur
loss
endstag
renal
diseas
criteria
neutrophil
gelatinaseassoci
lipocalin
erythrocyt
infect
patient
sickl
cell
diseas
receiv
monthli
red
blood
cell
rbc
transfus
present
venoocclus
crise
multiorgan
failur
patient
diagnos
hemolyt
transfus
reaction
transfusiontransmit
infect
confirm
plasmodium
falciparum
metaanalysi
observ
studi
demonstr
rbc
transfus
associ
higher
risk
allcaus
mortal
acut
coronari
syndrom
adjust
rr
ci
hr
ci
rr
ci
respect
compar
blood
transfus
howev
hemoglobinstratifi
analys
show
rbc
transfus
might
either
benefici
neutral
effect
mortal
hemoglobin
gdl
rr
ci
prospect
random
trial
perform
finland
evalu
two
studi
group
rbc
transfus
threshold
either
hemoglobin
gl
periop
cardiac
surgic
patient
signific
differ
intraop
postop
bleed
baselin
coagul
laboratori
valu
howev
patient
hemoglobin
threshold
gl
group
receiv
significantli
rbc
transfus
oper
two
patient
group
requir
resternotomi
due
bleed
first
h
surgeri
one
patient
hemoglobin
gl
group
postop
myocardi
infarct
stelev
review
postliv
transplant
pulmonari
complic
identifi
rbc
transfus
independ
risk
factor
prolong
ventil
time
mortal
pulmonari
complic
relat
pulmonari
edema
viral
pneumonia
rbc
transfus
greater
unit
case
report
patient
known
factor
x
defici
menorrhea
receiv
unit
rbc
anemia
unit
fresh
frozen
plasma
ffp
menorrhagia
subsequ
develop
hypertens
gener
tonicclon
convuls
magnet
reson
imag
find
consist
posterior
revers
encephalopathi
syndrom
pre
derang
blood
glucos
liver
function
test
also
note
recent
review
identifi
oxid
injuri
necrot
enterocol
sever
intraventricular
hemorrhag
retinopathi
prematur
transfus
relat
acut
lung
injuri
iron
overload
potenti
risk
rbc
transfus
preterm
babi
thu
need
restrict
transfus
guidelin
emphas
minim
risk
metaanalysi
observ
studi
report
associ
rbc
transfus
necrot
enterocol
preterm
infant
ci
p
studi
includ
metaanalysi
predominantli
lowtomoder
qualiti
observ
studi
retrospect
analysi
granulocyt
transfus
evalu
patient
neutropenia
secondari
chemotherapi
hematopoiet
stem
cell
transplant
underli
diseas
proven
probabl
bacteri
fungal
infect
improv
treatment
antimicrobi
expect
durat
neutropenia
least
day
patient
improv
regard
infect
overal
surviv
rate
day
respect
two
patient
experienc
dyspnea
increas
heart
rate
decreas
blood
pressur
total
patient
receiv
granulocyt
transfus
hematopoiet
stem
cell
transplant
one
patient
suffer
grade
iv
acut
graftvshost
diseas
agvhd
patient
suffer
grade
agvhd
one
patient
die
sever
pulmonari
infect
patient
die
due
myocard
patient
receiv
granulocyt
transfus
hematopoiet
stem
cell
transplant
one
patient
suffer
grade
ii
agvhd
patient
experienc
limit
chronic
graftvshost
diseas
cgvhd
one
recov
die
multipl
organ
dysfunct
syndrom
patient
die
due
thrombot
thrombocytopen
purpura
recent
cochran
review
random
control
trial
trial
particip
compar
platelet
transfus
open
control
acut
spontan
intracerebr
hemorrhag
associ
antiplatelet
drug
trial
platelet
transfus
associ
signific
increas
death
depend
modifi
rankin
scale
score
day
observ
studi
platelet
transfus
reaction
netherland
total
transfus
reaction
report
platelet
concentr
store
plasma
plasmaplt
compar
platelet
concentr
store
platelet
addit
solut
pa
two
differ
manufactur
pasbplt
pascplt
studi
found
statist
differ
rate
transfusionrel
circulatori
overload
transfusionrel
acut
lung
injuri
acut
hemolyt
reaction
delay
hemolyt
reaction
suspect
infect
pasbplt
transfus
compar
plasmaplt
transfus
overal
rel
risk
rr
transfus
reaction
ci
pascplt
compar
plasmaplt
rr
ci
transfus
reaction
pascplt
compar
pasbplt
reaction
rr
ci
hemoglobinbas
oxygen
carrier
hboc
rbc
transfus
mainstay
treatment
lifethreaten
anemia
manag
patient
accept
rbc
transfus
remain
medic
challeng
hboc
altern
therapi
receiv
rbc
transfus
use
publish
multipl
clinic
trial
recent
year
howev
evid
hboc
administr
critic
ill
patient
sickl
cell
diseas
scarc
case
seri
critic
ill
patient
receiv
hboc
sickl
cell
crisi
report
two
patient
receiv
unit
hboc
patient
receiv
unit
hboc
first
patient
experienc
hypertens
first
unit
administr
methemoglobinemia
receiv
unit
resolv
appropri
treatment
second
patient
also
develop
hypertens
mean
arteri
pressur
mmhg
resolv
without
treatment
lastli
third
patient
develop
carboxyhemoglobinemia
methemoglobinemia
unit
hboc
patient
treat
oral
ascorb
acid
three
patient
surviv
di
alpha
alpha
defici
genet
condit
affect
multipl
organ
system
includ
lung
liver
first
recogn
patient
emphysema
purifi
alpha
proteinas
inhibitor
implic
slow
progress
emphysema
previou
studi
report
chill
urticari
rash
fatigu
nausea
vomit
common
advers
effect
addit
rare
episod
igemedi
anaphylaxi
iga
relat
anaphylaxi
report
patient
iga
defici
recent
review
antiproteas
antitrypsin
augment
therapi
identifi
addit
advers
event
hereditari
angioedema
genet
defici
dysfunct
esteras
inhibitor
protein
lead
laryng
edema
associ
upper
airway
swell
sever
case
case
report
femal
present
oropharyng
facial
swell
success
treat
unit
esteras
inhibitor
protein
concentr
initi
patient
respond
intramuscular
epinephrin
intraven
fluid
antihistamin
steroid
measur
serum
esteras
inhibitor
administr
esteras
inhibitor
protein
concentr
lower
refer
rang
mgdl
respect
advers
event
note
administr
esteras
inhibitor
protein
concentr
use
esteras
inhibitor
protein
evalu
nonhereditari
angioedema
normal
esteras
inhibitor
inhibit
bradykinin
format
review
articl
includ
therapi
ecallantid
icatib
esteras
inhibitor
fresh
frozen
plasma
ffp
tranexam
acid
omalizumab
treatment
angiotensinconvert
enzym
inhibitorinduc
angioedema
idiopath
angioedema
angioedema
wheal
safeti
data
avail
articl
patient
receiv
esteras
inhibitor
none
patient
report
experi
advers
event
cryoprecipit
commonli
use
plasma
product
replac
fibrinogen
north
america
sinc
cryoprecipit
undergo
pathogen
reduct
process
risk
associ
infect
due
safeti
concern
european
countri
util
purifi
human
fibrinogen
concentr
therapeut
choic
howev
headtohead
comparison
cryoprecipit
purifi
human
fibrinogen
concentr
establish
phase
iii
noninferior
random
comparison
new
fibrinogen
concentr
vs
cryoprecipit
treat
acquir
hypofibrinogenemia
bleed
cardiac
surgic
patient
ongo
studi
may
help
solv
curios
efficaci
safeti
fibrinogen
replac
therapi
fibrinogen
replenish
surgeri
fibr
aim
recruit
approxim
patient
provid
power
detect
noninferior
fibrinogen
concentr
cryoprecipit
infect
singl
center
retrospect
analysi
outcom
conduct
compar
fresh
frozen
plasma
octaplaslg
solventdeterg
blood
group
specif
plasma
pediatr
cardiac
surgic
patient
total
pediatr
patient
year
age
includ
analysi
patient
octaplaslg
group
patient
ffp
group
statist
differ
amount
intraop
rbc
platelet
cryoprecipit
transfus
use
immedi
postop
coagul
intern
normal
ratio
inr
activ
partial
thromboplastin
time
aptt
significantli
lower
octaplaslg
group
vs
ffp
group
inr
vs
p
aptt
vs
p
patient
ffp
group
receiv
addit
plasma
transfus
first
h
vs
octaplaslg
group
vs
p
higher
rate
postop
infect
ffp
group
octaplaslg
group
vs
review
random
control
trial
evalu
efficaci
safeti
he
vs
normal
salin
critic
ill
patient
result
show
patient
he
group
met
rifl
risk
injuri
failur
loss
endstag
kidney
diseas
criteria
risk
injuri
p
two
random
control
trial
compar
he
normal
salin
show
statist
differ
allcaus
mortal
number
patient
met
rifl
criteria
random
singlecent
trial
conduct
compar
he
acet
ringer
solut
cardiopulmonari
bypass
prime
solut
total
patient
includ
trial
patient
group
result
show
prime
he
lower
fluid
load
bypass
he
group
ml
vs
acet
ringer
solut
group
ml
p
improv
cardiac
function
earli
postop
period
he
group
lminm
vs
acet
ringer
solut
group
lminm
p
ten
patient
he
group
patient
acet
ringer
solut
group
experienc
atrial
fibril
six
patient
he
group
patient
acet
ringer
solut
group
receiv
erythrocyt
concentr
transfus
periop
postop
period
statist
differ
howev
three
patient
develop
acut
kidney
injuri
he
group
exploratori
post
hoc
subgroup
analysi
prospect
trial
evalu
function
renal
paramet
structur
biomark
alphaglutathion
stransferas
kidney
injuri
liver
fatti
acidbind
protein
neutrophil
gelatinaseassoci
lipocalin
patient
coronari
arteri
bypass
graft
receiv
either
he
crystalloid
solut
differ
mortal
acut
kidney
injuri
need
renal
replac
therapi
function
structur
renal
paramet
two
group
liver
fatti
acidbind
protein
higher
he
group
crystalloid
group
h
postop
vs
p
blood
coagul
paramet
significantli
compromis
he
group
median
factor
ii
he
vs
crystalloid
p
median
factor
x
he
vs
crystalloid
p
median
thrombocyt
he
gptl
vs
crystalloid
gptl
p
blood
loss
vasopressor
dose
report
higher
he
group
howev
statist
signific
gelatin
synthet
colloid
plasma
expand
use
fluid
resuscit
although
recent
systemat
review
state
gelatin
associ
increas
mortal
resuscit
critic
ill
patient
clinic
concern
gelatin
reduc
clot
strength
vitro
analysi
succinyl
gelatin
sg
solut
compar
normal
salin
hemodilut
conduct
use
rotat
thromboelastometri
whole
blood
sampl
healthi
volunt
obtain
dilut
either
sg
solut
normal
salin
coagul
time
ct
clot
format
time
cft
alpha
angl
maximum
clot
firm
mcf
measur
ct
prolong
dilut
sg
solut
compar
whole
blood
mean
sg
solut
vs
whole
blood
p
cft
progress
prolong
dilut
dilut
mean
cft
sg
vs
whole
blood
p
mean
alphaangl
decreas
hemodilut
sg
compar
whole
blood
sg
whole
blood
p
mean
mcf
reduc
sg
hemodilut
compar
whole
blood
sg
mm
vs
whole
blood
mm
p
mcf
analysi
also
reduc
hemodilut
sg
compar
whole
blood
mean
sg
mm
vs
whole
blood
mm
p
mcf
reduc
hemodilut
normal
salin
normal
salin
mean
mm
vs
whole
blood
p
neurolog
case
immunoglobulininduc
asept
mening
report
patient
past
medic
histori
system
lupu
erythematosu
sle
associ
sjogren
syndrom
recent
worsen
asymptomat
hypogammaglobulinemia
secondari
rituximab
patient
start
intraven
immunoglobulin
ivig
gkg
consecut
day
replac
therapi
thirtysix
hour
first
infus
patient
present
emerg
depart
headach
photophobia
nausea
vomit
fever
along
neck
stiff
without
focal
neurolog
sign
lumbar
punctur
conduct
reveal
csf
analysi
neutrophil
pleocytosi
cellsmm
neutrophil
hyperproteinorrachia
mgdl
mildli
reduc
glucos
mgdl
consist
asept
mening
infecti
diseas
laboratori
result
neg
repeat
lumbar
punctur
result
day
show
normal
csf
analysi
commerci
avail
ivig
product
includ
lyophil
formul
requir
time
reconstitut
liquid
formul
requir
higher
volum
fluid
infus
new
ivig
solut
introduc
augment
limit
older
product
yield
highpur
glycinestabil
human
ivig
pharmacokinet
safeti
profil
new
product
analyz
prospect
openlabel
nonrandom
multicent
phase
iii
trial
includ
patient
common
variabl
immunodefici
xlink
agammaglobulinemia
depend
previou
ivig
dose
patient
either
receiv
ivig
infus
everi
n
week
n
month
advers
event
occur
infus
total
number
infus
headach
abund
report
infus
patient
group
higher
incid
seriou
advers
event
vs
includ
death
persist
signific
disabilityincapac
requir
hospit
prolong
exist
hospit
import
medic
event
howev
patient
group
sever
advers
event
vs
defin
mark
limit
activ
requir
assist
medic
intervent
therapi
two
patient
requir
premed
infus
postauthor
toler
safeti
analysi
ivig
octagam
subgroup
patient
n
immun
thrombocytopenia
itp
observ
monitor
focu
thromboembol
event
mean
dose
octagam
gkginfus
total
event
report
result
advers
drug
reaction
occurr
rate
infus
common
advers
drug
reaction
back
pain
n
headach
n
addit
nausea
dizzi
sensat
heavi
also
report
thromboembol
event
seriou
advers
drug
reaction
kawasaki
diseas
rare
diseas
state
associ
acut
vascul
lead
multipl
organ
dysfunct
diseas
carri
potenti
caus
pleural
effus
one
complic
howev
case
japan
report
year
pediatr
patient
develop
pleural
effus
right
infus
ivig
acut
symptom
subsid
patient
receiv
gkg
ivig
signific
pleural
effus
note
chest
radiographi
comput
tomographi
h
complet
therapi
patient
experienc
mild
dyspnea
low
oxygen
satur
room
air
total
ml
exud
pleural
fluid
drain
fluid
serum
ratio
ivig
therapi
use
initi
therapi
kawasaki
diseas
although
evid
well
establish
current
clinic
practic
infliximab
shown
well
toler
patient
phase
iii
random
openlabel
activecontrol
parallelgroup
multicent
trial
conduct
compar
infliximab
ivig
japanes
patient
kawasaki
diseas
persist
fever
initi
dose
ivig
patient
receiv
singl
dose
infliximab
mgkg
n
polyethylen
glycoltr
human
immunoglobulin
vgih
n
gkg
day
defervesc
rate
within
h
greater
infliximab
vgih
vs
p
defervesc
achiev
earlier
infliximab
p
advers
event
report
patient
infliximab
group
patient
vgih
group
relaps
kawasaki
diseas
occur
one
patient
vgih
group
infus
reaction
infect
report
vgih
group
respect
compar
infliximab
group
respect
patient
splenic
margin
zone
lymphoma
develop
acut
thrombocytopenia
upon
administr
intratect
ivig
hypogammaglobulinemia
nadir
count
platelet
l
immunofluoresc
test
appli
flow
cytometri
monoclon
antibodi
immobil
platelet
antigen
assay
show
strong
direct
bind
reaction
patient
platelet
intratect
igg
subcutan
immunoglobulin
scig
provid
altern
deliveri
method
patient
toler
intraven
administr
requir
formul
administ
home
studi
util
scig
compar
ivig
primari
immunodefici
syndrom
report
fewer
advers
effect
howev
heterogen
scig
formul
studi
popul
lead
larg
varianc
report
incid
addit
advantag
includ
opportun
ambulatori
infus
lower
health
care
cost
need
premed
van
schaik
colleagu
conduct
intern
multicent
random
doubleblind
placebocontrol
studi
hizentra
patient
chronic
inflammatori
demyelin
polyneuropathi
cidp
path
studi
random
patient
placebo
lowdos
scig
gkg
highdos
scig
gkg
low
high
dose
demonstr
statist
lower
probabl
diseas
relaps
week
rel
placebo
howev
low
high
dose
scig
group
experienc
greater
incid
treatment
emerg
advers
effect
vs
placebo
vs
low
high
dose
respect
gener
disord
condit
fatigu
vs
local
site
reaction
vs
infect
vs
musculoskelet
disord
vs
total
six
patient
present
seriou
advers
effect
one
observ
placebo
group
three
low
dose
two
high
dose
group
howev
one
acut
allerg
dermatolog
reaction
low
dose
group
deem
causal
relat
larg
retrospect
cohort
studi
sponsor
us
food
drug
administr
fda
identifi
health
care
claim
commerci
insur
patient
unit
state
expos
ivig
andor
scig
januari
may
use
gammagard
liquid
ivig
refer
investig
find
statist
signific
differ
adjust
rate
hemolyt
reaction
hizentra
scig
includ
analysi
ci
studi
suggest
hizentra
associ
lower
risk
hemolyt
reaction
compar
ivig
product
studi
would
need
confirm
dimou
colleagu
describ
singlecent
retrospect
review
scig
administ
patient
hypogammaglobulinemia
secondari
hematolog
malign
scig
dose
mgkgmonth
recombin
human
hyaluronidas
pretreat
achiev
igg
trough
level
near
mgdl
uncompl
infus
record
infect
document
six
patient
igg
level
mgdl
time
infect
three
patient
present
mild
grade
adr
consist
lowgrad
fever
headach
even
follow
initi
second
scig
infus
local
edema
follow
subcutan
infus
mild
resolv
within
h
infus
one
male
patient
report
unilater
scrotal
edema
hour
infus
resolv
less
h
fibrinogen
concentr
prefer
therapeut
treatment
fibrinogen
replac
congenit
fibrinogen
defici
prospect
multin
phase
iii
trial
new
plasmaderiv
doubl
virusinactiv
human
fibrinogen
concentr
conduct
evalu
efficaci
safeti
use
ondemand
treatment
bleed
episod
surgic
prophylaxi
congenit
afibrinogenemia
patient
thirteen
patient
includ
evalu
result
treatment
success
ci
death
thrombos
seroconvers
report
singlecent
retrospect
studi
evalu
outcom
prophylact
fibrinogen
concentr
infus
patient
undergon
heart
transplant
patient
patient
receiv
preoper
fibrinogen
concentr
g
termin
cardiopulmonari
bypass
pump
complet
revers
heparin
patient
compar
control
group
n
fibrinogen
group
shorter
length
hospit
stay
vs
day
p
fewer
number
pack
rbc
infus
vs
unit
p
howev
patient
fibrinogen
group
develop
aki
surgeri
compar
control
group
though
number
statist
signific
p
studi
n
egrier
et
al
evalu
safeti
clottafact
current
medic
practic
clottafact
human
plasmaderiv
fibrinogen
concentr
obtain
plasma
fraction
cryosupernat
precipit
ionexchang
chromatographi
patient
includ
acquir
fibrinogen
defici
acut
bleed
agre
sign
inform
consent
form
studi
includ
patient
accord
type
treatment
cur
prevent
origin
bleed
patient
receiv
cur
treatment
consid
success
moder
respons
overal
two
patient
experienc
advers
drug
event
case
pulmonari
embol
venou
thromboembol
case
seri
compil
evalu
efficaci
manag
spontan
hemoptysi
procedur
relat
bleed
via
instil
endobronchi
gelatin
thrombin
slurri
gt
case
identifi
period
year
gt
use
standard
care
cold
salin
epinephrin
balloon
occlus
fail
case
due
spontan
bleed
diagnost
therapeut
procedur
overal
hemostasi
achiev
patient
advers
event
note
day
jhajharia
colleagu
evalu
use
human
thrombin
inject
patient
present
gastric
varic
bleed
studi
includ
total
patient
major
underli
hepat
diseas
patient
studi
receiv
session
mean
total
dose
iu
patient
achiev
hemostasi
initi
present
requir
repeat
endoscop
session
upon
followup
advers
reaction
relat
thrombin
inject
singl
center
retrospect
cohort
studi
conduct
assess
overal
incid
thromboembol
te
event
patient
receiv
recombin
factor
viia
rfviia
compar
refractori
coagulopath
bleed
orthotop
heart
transplant
oht
patient
evalu
receiv
rfviia
patient
identifi
control
group
studi
found
signific
differ
patient
receiv
rfviia
control
group
vs
p
howev
within
day
rfviia
patient
suffer
te
event
compar
control
group
p
author
conclud
differ
rate
te
event
oht
patient
nonsignific
trend
toward
higher
risk
earli
te
develop
rfviia
group
retrospect
collect
data
patient
traumat
brain
injuri
tbi
acquir
level
us
trauma
center
period
year
primari
outcom
inhospit
mortal
propens
score
conduct
overcom
differ
note
patient
receiv
recombin
factor
viia
rfviia
due
tbi
compar
total
patient
analyz
receiv
rfviia
differ
mortal
group
howev
improv
glascow
coma
scale
gc
admiss
discharg
less
among
receiv
rfviia
harper
colleagu
conduct
retrospect
propensitymatch
analysi
assess
mortal
follow
cardiac
surgeri
patient
receiv
threefactor
inact
prothrombin
complex
concentr
pcc
vs
recombin
activ
factor
vii
rfviia
total
patient
receiv
rfviia
receiv
pcc
undergo
cardiac
surgeri
requir
cardiopulmonari
bypass
signific
differ
mortal
group
rfviia
significantli
associ
renal
failur
requir
dialysi
p
increas
need
fresh
frozen
plasma
transfus
p
platelet
transfu
tied
worster
compil
literatur
complet
systemat
review
effect
recombin
factor
viia
rfviia
acquir
haemophilia
patient
overal
studi
met
inclus
criteria
encompass
patient
bleed
patient
receiv
rfviia
bleed
initi
dose
rfviia
ae
rfviia
favor
safeti
profil
low
risk
gener
advers
event
thromboembolicassoci
event
addit
demonstr
effect
haemophilia
patient
high
risk
excess
bleed
surgeri
zozulya
colleagu
conduct
propens
plan
analysi
nuwiq
simotocog
alfa
humancl
rhfviii
gener
rfviii
analysi
assess
efficaci
safeti
previou
treat
patient
ptp
sever
haemophilia
fviii
activ
underw
surgeri
patient
receiv
surgic
prophylaxi
nuwiq
efficaci
evalu
surgeri
major
minor
success
rate
hemostat
efficaci
assess
excel
good
one
major
surgeri
studi
identifi
seriou
treatmentrel
advers
event
none
patient
develop
fviii
inhibitor
multiphas
studi
conduct
includ
pharmacokinet
pk
phase
random
doubleblind
crossov
comparison
trenonacog
alfa
nonacog
alfa
recombin
fix
follow
washout
period
treatment
ae
iukg
follow
second
washout
period
day
patient
enter
openlabel
treatment
phase
receiv
prophylact
ondemand
prophylaxi
dose
consist
iukg
twice
weekli
compar
iukg
ondemand
treatment
bleed
base
sever
commonli
seen
side
effect
headach
report
fix
inhibitor
prophylaxi
dose
deem
effect
prevent
bleed
median
annual
bleed
rate
ondemand
infus
resolv
bleed
overal
author
conclud
safe
efficaci
routin
prophylaxi
treatment
bleed
mahlangu
compil
review
literatur
regard
extend
halflif
ehl
recombin
factor
ix
rfix
product
treatment
haemophilia
b
multipl
clinic
trial
assess
ehl
rfix
indic
safeti
profil
product
accept
allerg
reaction
thromboembol
phenomena
neutral
antibodi
addit
agent
reduc
treatment
burden
haemophilia
b
studi
ongo
regard
safeti
efficaci
previous
untreat
patient
role
therapi
compar
novel
agent
remain
establish
thromboembol
fourfactor
prothrombin
complex
concentr
contain
coagul
factor
ii
vii
ix
x
indic
revers
vitamin
k
antagonist
associ
bleed
effect
rapid
inr
correct
risk
venou
arteri
thromboembol
event
present
manufactur
recommend
use
repeat
dose
reason
well
lack
clinic
data
adult
patient
anticoagul
apixaban
patient
receiv
two
dose
dose
unitskg
approxim
day
apart
pulmonari
hemorrhag
patient
experienc
cardiac
arrest
day
admiss
presum
massiv
pulmonari
embol
base
echocardiogram
find
addit
onlabel
use
warfarin
revers
recent
review
offlabel
use
patient
experienc
coagulopathi
warfarin
therapi
retrospect
studi
patient
incid
thromboembol
complic
vs
p
differ
amongst
patient
receiv
onlabel
offlabel
use
thromboembol
event
total
lower
extrem
symptomat
dvt
upper
extrem
dvt
evalu
offlabel
use
patient
receiv
receiv
nonwarfarin
relat
inr
elev
dvt
event
amongst
cohort
patient
retrospect
studi
patient
leftventricular
assist
devic
undergo
orthotop
heart
transplant
patient
requir
warfarin
revers
receiv
either
intraop
product
alon
ffp
group
requir
less
ffp
cryoprecipit
pack
red
blood
cell
thrombot
event
note
altern
dose
scheme
includ
fixeddos
strategi
strategi
recent
evalu
retrospect
review
patient
receiv
unit
fixeddos
warfarin
revers
thrombot
complic
note
studi
von
willebrand
factor
vwf
factor
viii
concentr
von
willebrand
factor
vwf
multimer
plasma
protein
regul
platelet
adhes
collagen
expos
vascular
injuri
complex
fviii
serv
shield
prematur
degrad
circul
vwffviii
concentr
use
revers
quantit
qualit
defect
von
willebrand
diseas
vwd
hemophilia
thu
restor
hemostat
capac
hazendonk
colleagu
conduct
multicent
retrospect
cohort
studi
evalu
periop
manag
patient
treat
haemat
p
netherland
vwffviii
dose
achiev
preoper
mainten
level
iuml
patient
review
total
bleed
event
occur
associ
hemoglobin
drop
mmoll
andor
necessit
blood
transfus
thrombot
event
record
despit
patient
reach
extrem
high
fviii
level
iuml
howev
thromboprophylaxi
low
molecular
weight
heparin
initi
patient
prospect
openlabel
nonrandom
multin
studi
octan
human
plasmaderiv
vwffviii
concentr
conduct
previous
untreat
caucasian
male
hemophilia
assess
immunogen
formul
mean
dose
iukgexposur
day
ed
administ
indic
prophylaxi
immun
toler
induct
bleed
surgic
procedur
inhibitor
detect
five
patient
three
present
clinic
relev
titer
inhibitor
advers
effect
report
patient
consid
probabl
possibl
relat
vwffviii
infus
note
case
asymptomat
parvoviru
seroconvers
occur
howev
toler
consid
good
document
infus
one
observ
cohort
studi
examin
vwffviii
newborn
congenit
heart
diseas
chd
anatom
defect
may
increas
blood
shear
stress
thu
induc
acquiredvon
willebrand
syndrom
avw
twelv
complex
chd
patient
requir
cardiopulmonari
bypass
cbp
surgeri
includ
review
receiv
intraop
vwffviii
cumul
dose
iukg
signific
relationship
observ
dose
factor
concentr
chest
closur
time
blood
loss
one
thrombot
complic
transient
cerebr
venou
sinu
thrombosi
note
patient
receiv
also
rfvii
antithrombin
iii
inhibit
serin
proteas
within
coagul
cascad
eg
thrombin
plasmin
factor
ixa
xa
etc
avail
unit
state
human
plasma
deriv
thrombat
iii
recombin
antithrombin
atryn
atryn
indic
sole
prevent
periop
postpartum
thrombosi
patient
hereditari
antithrombin
defici
thrombat
iii
addit
indic
treatment
prevent
thromboembol
current
japanes
clinic
practic
guidelin
sepsi
manag
recommend
antithrombin
replac
therapi
patient
experienc
sepsisassoci
dic
japanes
case
seri
five
patient
antithrombin
defici
undergo
major
cardiovascular
surgeri
investig
administ
antithrombin
iii
concentr
prior
surgeri
maintain
atiii
activ
respect
earli
periprocedur
complic
note
howev
one
patient
present
month
follow
bioprosthet
aortic
valv
replac
numer
thrombi
valv
leaflet
necessit
replac
mechan
valv
cardiovascular
erythropoietin
epo
hematopoiet
factor
commonli
use
treat
anemia
associ
chronic
kidney
diseas
ckd
epo
known
cardiovascular
advers
effect
use
target
hemoglobin
level
gdl
metaanalysi
studi
report
find
increas
cardiovascular
risk
differ
risk
amongst
differ
epo
agent
trial
patient
sever
traumat
brain
injuri
random
either
epo
unit
day
vs
placebo
differ
either
neurolog
outcom
thromboembol
event
week
multicent
openlabel
random
phase
trial
weekli
apixaban
alfa
patient
squamou
cell
carcinoma
manag
radiat
therapi
poorer
outcom
found
amongst
darbepoetin
treat
patient
compar
placebo
trial
patient
treat
darbepoetin
alfa
patient
control
group
trial
halt
earli
due
patient
darbepoetin
arm
experienc
tumor
progress
increas
mortal
immun
thrombocytopenia
itp
disord
primari
natur
secondari
autoimmun
diseas
infect
drug
thrombopoietin
receptor
agonist
tpora
one
mainstay
treatment
chronic
itp
avail
tpora
includ
eltrombopag
romiplostim
consid
second
line
agent
chronic
itp
metaanalysi
random
placebocontrol
trial
evalu
safeti
outcom
eltrombopag
romiplostim
placebo
advers
event
studi
headach
fatigu
thrombosi
arthralgia
nausea
nasopharyng
diarrhea
peripher
edema
epistaxi
pain
extrem
dizzi
contus
upper
abdomin
pain
upper
respiratori
tract
infect
cough
myalgia
anxieti
back
pain
statist
signific
differ
tpora
placebo
retrospect
studi
patient
treat
either
eltrombopag
romiplostim
commonli
report
advers
event
headach
transient
transaminas
elev
thromboembol
eltrombopag
arm
experienc
headach
experienc
transamin
thromboembol
includ
dvt
acut
mi
pe
superfici
thrombophleb
romiplostim
arm
experienc
headach
experienc
transamin
thromboembol
includ
dvt
pe
differ
rate
headach
transamin
statist
signific
thromboembol
itp
possibl
complic
sle
also
associ
antiphospholipid
syndrom
retrospect
review
patient
treat
tpora
sle
itp
experienc
seriou
thrombot
advers
event
arteri
thrombosi
event
includ
mi
stroke
catastroph
ap
occur
patient
antiphospholipid
syndrom
two
venou
thrombosi
event
occur
patient
without
ap
base
result
author
conclud
altern
therapi
patient
ap
consid
systemat
review
random
control
trial
pediatr
patient
treat
tpora
efficaci
similar
eltrombopag
romiplostim
eltrombopag
display
lower
risk
overal
well
clinic
signific
bleed
compar
romiplostim
statist
signific
like
due
underli
diseas
rather
drug
effect
tpora
advers
effect
differ
eltrombopag
romiplostim
treat
patient
cough
much
frequent
eltrombopag
arm
rr
p
observ
trial
patient
aplast
anemia
conduct
evalu
realworld
use
high
dose
median
mg
eltrombopag
patient
popul
common
advers
event
seen
skin
hyperpigment
appear
dose
depend
occur
patient
treat
eltrombopag
least
mgday
effect
fulli
revers
eltrombopag
discontinu
dyspepsia
requir
treatment
acidsuppress
medic
occur
patient
case
requir
discontinu
hepatotox
requir
eltrombopag
discontinu
occur
patient
aspir
studi
phase
random
placebocontrol
trial
patient
test
eltrombopag
advanc
myelodysplast
syndrom
acut
myeloid
leukemia
sever
thrombocytopenia
seriou
advers
effect
occur
eltrombopag
treat
patient
vs
placebotr
patient
seven
eltrombopag
patient
seriou
advers
event
thought
relat
studi
drug
acut
kidney
injuri
arteri
thrombosi
bone
pain
diarrhea
myocardi
infarct
pyrexia
retin
vein
occlus
hematopoiet
stem
cell
transplant
hsct
effect
treatment
option
blood
cancer
hematopoiet
diseas
autoimmun
ill
signific
advanc
posttranspl
care
led
decreas
mortal
immedi
period
transplant
despit
patient
undergo
hsct
still
higher
risk
death
gener
popul
earli
late
transplant
retrospect
cohort
pediatr
patient
underw
hsct
patient
allogen
hsct
compar
patient
underw
autolog
hsct
allohsct
statist
signific
higher
rate
sever
bacteri
infectionsepsi
compar
auto
hsct
vs
viral
reactiv
pediatr
patient
undergo
hsct
risk
sever
endocrin
disord
includ
insulin
resist
hypothyroid
hypogonad
hypocortisol
retrospect
review
patient
develop
least
one
endocrin
disord
median
followup
patient
year
common
primari
gonad
failur
patient
develop
hypogonad
perman
hypothyroid
occur
patient
hypocortisol
occur
patient
type
diabet
occur
patient
dyslipidemia
also
common
occur
patient
metabol
syndrom
addit
late
complic
also
occur
rel
earli
hsct
prospect
studi
allogen
autolog
hsct
patient
observ
metabol
syndrom
baselin
day
number
increas
patient
metabol
syndrom
associ
insulin
resist
incid
higher
patient
underw
allogen
transplant
compar
autolog
transplant
cardiovascular
mortal
hsct
patient
doubl
gener
popul
retrospect
studi
consecut
hsct
patient
develop
cardiovascular
diseas
within
year
transplant
index
date
follow
onset
cardiovascular
diseas
death
year
whichev
came
first
overal
patient
develop
cardiovascular
diseas
heart
failur
coronari
arteri
diseas
followup
period
facil
collect
manufactur
blood
strict
guidanc
food
drug
administr
fda
ensur
uniform
prepar
blood
steril
reduc
risk
blood
contamin
infecti
diseas
unit
state
donat
blood
test
myriad
infecti
pathogen
hiv
hepat
b
viru
hbv
zika
sinc
incept
test
diseas
transmit
blood
transfus
rate
infect
declin
tremend
year
develop
countri
due
storag
room
temperatur
platelet
possess
highest
risk
bacteri
contamin
limit
storag
day
instanc
risk
unit
platelet
contamin
risk
septic
transfus
reaction
reaction
sever
fatal
advanc
year
reduc
pathogen
transmiss
due
screen
effort
pathogen
reduct
product
rate
viral
pathogen
transmiss
remain
quit
low
rate
million
howev
bacteria
still
remain
problem
continu
effort
improv
blood
safeti
use
pathogen
reduct
system
new
laboratori
test
analysi
conduct
american
red
cross
blood
donat
allogen
englishspeak
nonmilitari
donor
june
april
assess
rate
hepat
b
viru
hbv
dnaposit
recent
rbi
occult
obi
hbv
infect
blood
donat
test
hbv
surfac
antigen
hbsag
core
antibodi
antihbc
confirm
via
neutral
test
hbsag
hbv
dna
nucleicacid
amplif
test
nat
total
allogen
donat
collect
aforement
timefram
overal
rbi
per
donat
n
obi
rate
per
n
rbi
obi
rate
constitut
hbvinfect
donor
n
author
conclud
rate
rbi
obi
continu
detect
confirm
import
comprehens
hbv
dna
screen
rapid
pandem
spread
zika
viru
zikv
intern
public
health
emerg
enact
due
possibl
case
transmit
via
blood
transfus
brazil
question
rais
possibl
risk
blood
suppli
initi
fda
ceas
blood
donat
area
unit
state
zikv
activ
sinc
implement
screen
donat
blood
zikv
base
previou
literatur
current
strategi
unit
state
appear
costli
unclear
gain
question
surround
appropri
screen
possibl
revers
requir
even
though
zikv
elimin
epidem
wane
substanti
number
report
local
acquir
case
continent
unit
state
decreas
mere
howev
precautionari
principl
riskbas
approach
encourag
continu
review
literatur
new
data
emerg
